Wharton's jelly

REGENATIVE LABS' LATEST PUBLISHED STUDY DEMONSTRATES THE SAFETY AND EFFICACY OF WHARTON'S JELLY CONNECTIVE TISSUE ALLOGRAFT FOR ROTATOR CUFF TEARS

Retrieved on: 
Thursday, April 4, 2024
Knee, MDPI, Stiffness, Shoulder, Safety, Hip, Wharton's jelly, Rotator cuff, Patient, Research, Rehabilitation, Quality of life, Manager, Efficacy, WOMAC, Regenerative medicine, Quality, Literature, Spine, Orthopedic surgery, Pain, Calendar, Physician, Injury, WJ, Medicine, Dentistry

PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.

Key Points: 
  • PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.
  • Patients in need of rotator cuff repairs often seek minimally invasive options, making Wharton's Jelly a promising alternative for musculoskeletal defects.
  • Utilizing the structural connective tissue allografts has allowed many patients to avoid surgery altogether and significantly improve their quality of life."
  • The study titled "Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears," was published by MDPI and can be accessed in its entirety here.

REGENATIVE LABS, TOGETHER WITH THE PAIN AND SLEEP THERAPY CENTER, PUBLISHES CASE STUDY DEMONSTRATING NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN TEMPOROMANDIBULAR JOINT DEFECTS

Retrieved on: 
Thursday, October 26, 2023
Temporomandibular joint, Mouth, Physician, Head, Osteoarthritis, Pathology, Temporomandibular joint dysfunction, Publication, Umbilical cord, Injection, Massage, Research, PRF, Wharton's jelly, Reynolds, Subluxation, Medicine, NP, Patient, Muscular system, TMD, Today, Dentistry, Medical imaging, Nursing, Veterinary medicine, Jelly, Pain, TMJ, Regenerative medicine

PENSACOLA, Fla., Oct. 26, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a case study demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects. The case study titled "Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study," was published by Walsh Medical Media and can be accessed in its entirety here.

Key Points: 
  • PENSACOLA, Fla., Oct. 26, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a case study demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.
  • The case study titled "Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study," was published by Walsh Medical Media and can be accessed in its entirety here.
  • After one application of Regenative's Wharton's Jelly allograft, the patient's pain improved by an average of 75% after 90 days.
  • "A few years ago, we started using PRF (platelet-rich fibrin) therapy in the jaw joint, and we thought that was revolutionary.

REGENATIVE LABS, TOGETHER WITH THE PAIN AND SLEEP THERAPY CENTER, ANNOUNCE NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN TEMPOROMANDIBULAR JOINT DEFECTS

Retrieved on: 
Tuesday, October 3, 2023
Injection, TMD, Muscular system, Umbilical cord, Physician, Pathology, Head, Osteoarthritis, Research, Medicine, Reynolds, Today, Massage, Temporomandibular joint, PRF, Publication, Patient, Temporomandibular joint dysfunction, Wharton's jelly, NP, Subluxation, Mouth, Dentistry, Medical imaging, Nursing, Veterinary medicine, Regenerative medicine, Jelly, TMJ, Pain

PENSACOLA, Fla., Oct. 3, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.

Key Points: 
  • PENSACOLA, Fla., Oct. 3, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.
  • Standard treatment includes simply resting the jaw muscles and avoiding use, massage, physical therapy, medication management, and, when all else fails, surgery.
  • After one application of Regenative's Wharton's Jelly allograft, the patient's pain improved by an average of 75% after 90 days.
  • "A few years ago, we started using PRF (platelet-rich fibrin) therapy in the jaw joint, and we thought that was revolutionary.

REGENATIVE LABS TO PRESENT ITS GROUNDBREAKING WHARTON'S JELLY STUDIES AT THE SYMPOSIUM ON ADVANCED WOUND CARE

Retrieved on: 
Monday, April 10, 2023
Granulation tissue, Breast reduction, Education, Regenerative medicine, SAWC, Research, Wharton's jelly, DLS, Manager, Patient, Symposium, Pharmaceutical industry, Medical imaging, Labs

PENSACOLA, Fla., April 10, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading provider of regenerative medicine solutions, announced that it will present two scientific studies demonstrating the efficacy of Wharton's jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.

Key Points: 
  • PENSACOLA, Fla., April 10, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading provider of regenerative medicine solutions, announced that it will present two scientific studies demonstrating the efficacy of Wharton's jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.
  • The first patient with a ten-year-old wound experienced a 94 percent decrease in wound volume despite noncompliant at-home care.
  • "We are excited to present these two groundbreaking studies at the SAWC conference," said Tyler Barrett, CEO of Regenative Labs.
  • Regenative Labs will present these studies at SAWC Spring | WHS, which will be held April 26–30 in National Harbor, Maryland.

REGENATIVE LABS ANNOUNCES CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN POST-SURGICAL BREAST REDUCTION

Retrieved on: 
Monday, December 12, 2022
Mammaplasty, Medical degree, Literature, Physician, Breast, Distress, Ministry of Education (Malaysia), AATB, Infection, American Academy, Patient, Mayo Clinic, Breast reduction, Hospital, Wharton's jelly, FDA, Pain, Johns Hopkins Hospital, American Board of Commissioners for Foreign Missions, Health, University, AOA, Mouth ulcer, Multimedia, Ulcer, Plastic, Structural Damage, Walter Reed Army Medical Center, Medical device, Medical imaging, Pharmaceutical industry, Labs, Regenerative medicine

PENSACOLA, Fla., Dec. 12, 2022 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces advancements in breast reduction post-surgical complication care.

Key Points: 
  • PENSACOLA, Fla., Dec. 12, 2022 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces advancements in breast reduction post-surgical complication care.
  • "With Wharton's Jelly, we were able to close a wound that would normally take 3 months, in 3 weeks," he concluded.
  • The average price of breast reduction is $7000 alone, with extra care incurring additional cost.
  • About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments.

StimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ P

Retrieved on: 
Thursday, August 27, 2020
Branches of biology, Biology, Embryology, Stem cells, Developmental biology, Wharton's jelly, Umbilical cord, Connective tissue, Umbilical, Cryo-Save

Corplex P, a shelf-stable Wharton's Jelly allograft obtained from donated human umbilical cord tissue, is intended for homologous use for the supplementation of connective tissue voids in open wound environments.

Key Points: 
  • Corplex P, a shelf-stable Wharton's Jelly allograft obtained from donated human umbilical cord tissue, is intended for homologous use for the supplementation of connective tissue voids in open wound environments.
  • Corplex P was born out of a growing and widespread demand for a conformable placental derived product.
  • Corplex, StimLabs' first umbilical cord product was launched in early Q1, and Corplex P, an umbilical cord derivative, is available today.
  • Corplex P is a Wharton's Jelly allograft obtained from donated human umbilical cord tissue.

Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical Cord Mesenchymal Stem Cells

Retrieved on: 
Monday, April 13, 2020
Embryology, Branches of biology, Biology, Human reproduction, Umbilical cord, Amniocentesis, Amniotic fluid, Wharton's jelly, Cord lining

Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.

Key Points: 
  • Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.
  • Respiratory distress kills hundreds of thousands of people each year worldwide.
  • Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration.
  • Predictives signature products are uniquely born from the Whartons jelly layer of the umbilical cord and amniotic fluid and tissue.

BioStem Technologies, Inc. to Attend 2020 Perinatal Stem Cell Society Conference

Retrieved on: 
Thursday, February 27, 2020
Branches of biology, Biology, Embryology, Life sciences, Stem cells, Wharton's jelly, Amniotic fluid, Cord blood, Amnion, Amniocentesis

Pompano Beach, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue-based allografts, today announced its attendance to the 2020 Perinatal Stem Cell Society Conference.

Key Points: 
  • Pompano Beach, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue-based allografts, today announced its attendance to the 2020 Perinatal Stem Cell Society Conference.
  • The speakers at this conference are some of the most important key opinion leaders in our field.
  • About International Perinatal Stem Cell Society, Inc.In 2013, the International Perinatal Stem Cell Society, Inc. a non-profit (501(c)(3) organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders.
  • Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/Wharton's jelly, as well as placental blood and placental tissue.